Who is sponsoring NCT00574834?

NCT00574834 is sponsored by University of Maryland, Baltimore.

What condition does NCT00574834 study?

NCT00574834 studies Metabolic Syndrome.

What drugs are being tested in NCT00574834?

Interventions: Ramipril, HCTZ-hydrochlorothiazide, Ramipril+HCTZ.

What is the status of NCT00574834?

NCT00574834 is currently TERMINATED.

Last reviewed 2019-09-10 · How we verify

Mechanisms of Reduced Ramipril on the Onset of Type 2 Diabetes Mellitis

NCT00574834 EARLY_PHASE1 TERMINATED Results posted

The study will be focused on determining the integrated in-vivo mechanisms responsible for Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels) glycemia in patients with impaired glucose tolerance. Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal glycemia in patients with impaired glucose tolerance.

Details

Lead sponsor	University of Maryland, Baltimore
Phase	EARLY_PHASE1
Status	TERMINATED
Enrolment	17
Start date	2007-03
Completion	2014-08

Conditions

Metabolic Syndrome

Interventions

Ramipril
HCTZ-hydrochlorothiazide
Ramipril+HCTZ

Primary outcomes

Changes in Insulin Sensitivity — 6 months
Measures of change in endogenous glucose production from baseline to final 30 minutes of clamp studies after 6 months of treatment.

Countries

United States